Evaluation of the therapeutic effect of integrated traditional Chinese and western medicine on macular edema of central retinal vein occlusion

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2022000018

Enrollment

Unknown

Registered

2022-06-17

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion-macular edema

Interventions

Treatment group:Intravitreal injection of rizumab injection combined with Quji Tongluo decoction.

Control group:Intravitreal injection of rizumab injection combined with placebo

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age: 30 and 75 years old; (2) Meet the diagnostic criteria for western medicine diagnosis of macular edema of central retinal vein obstruction in the diagnostic criteria and the diagnostic criteria of sputum and blood stasis syndrome syndrome; (3) Patients who voluntarily participate in the project study and have good compliance.

Exclusion criteria

Exclusion criteria: (1) Combined with keratitis, endophthalmitis and other active bacteria, viruses, fungal infections; (2) With macular hole, central serous chororetinopathy, diabetic retinopathy, retinopathy, retinal pigmentosa, and other fundus diseases affecting retinal detachment; (3) Combined with the refractive interstitial turbidity, and unable to complete the FFA or OCT inspection; (4) Whole-body or eye conditions are not suitable for room water extraction and testing; (5) Allergic to leezumab, fluorescein sodium contrast agent, or allergic to the components of the formula; (6) Suffering from serious heart, brain, liver, kidney, blood system and other systemic diseases; (7) With neurological and mental disorders, unable to cooperate or unwilling to cooperate; (8) Pregnant or lactating women or those with recent family plans; (9) Those who have participated in other clinical trials 3 months before selection, or other circumstances that the investigator considers unsuitable to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Macular foveal thickness;	—

Secondary

Measure	Time frame
Detection of blood flow density and optic disc blood flow in the macular area;Best-corrected visual acuity examination;Metabolomics examination of aqueous humor;Traditional Chinese medicine syndrome score;Fundus photo examination;	—

Countries

China

Contacts

Public ContactXie Like

Eye hospital of China Academy of Chinese Medical Sciences

bjxielike@sina.com13466782818

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026